VJNeurology Podcast

Breaking the Cycle: Debating Management Approaches in Medication Overuse Headache

Welcome to this episode of the VJ Sounds Podcast, brought to you by the Video Journal of Neurology (VJNeurology). In this podcast, we discuss the important subject of medication overuse headache (MOH). Discover insights into key debates in the field from renowned experts, Prof. Sait Ashina from Harvard Medical School, Prof. Morris Levin from the University of California, San Francisco, Alan Rappaport, University of California, Los Angeles, and Licia Grazzi, Fondazione IRRCS Istituto Neurologico Carlo Besta.

Examining evidence for EVT in MeVO stroke

The latest guidelines recommend endovascular thrombectomy (EVT) as the gold standard treatment approach for eligible patients with an acute ischemic stroke due to large vessel occlusion, but there is currently no robust randomized control data supporting its routine use in medium vessel occlusion (MeVO) strokes.  
In this podcast, stroke experts delve into current uncertainties surrounding the management of small- and medium-vessel strokes, namely optimal detection and treatment strategies. They discuss current guidelines, key debates, and ongoing randomized clinical trials assessing the efficacy of EVT in MeVO stroke.
With Johanna Ospel, MD, University of Calgary, Alberta, Canada; Nishita Singh, MD, University of Calgary, Alberta, Canada; and Jan Gralla, MD, Inselspital, University Hospital Bern, Bern, Switzerland.
 

Decoding epilepsy: a precision approach to management

Welcome to our latest episode of the Video Journal of Neurology podcast where we explore the rapidly evolving world of precision medicine within the field of epilepsy. In this episode, we delve into how our emerging understanding of genetic factors is reshaping our knowledge of epilepsy syndromes, shedding light on personalized treatment strategies.
Join us as Guido Rubboli, MD; Simona Balestrini, MD, PhD; Reetta Kälviäinen, MD, PhD; and Kristen Park, MD, share their invaluable perspectives on the cutting-edge advancements in precision medicine for epilepsy. Together, they unravel key advances, including the use of pharmacogenomics for decision making, the development of gene therapies, and the role of gene modifiers in phenotypic expression.
We hope you enjoy listening and find this episode useful.

Cluster headache management: current landscape & emerging therapies

Cluster headache, a rare and severe headache disorder, represents the most common trigeminal autonomic cephalalgia. Due to its rarity and often refractory nature, management can be challenging.In this episode, leading experts delve into acute and preventive treatment strategies for cluster headache. Emerging therapies are also discussed, including psilocybin and CGRP-targeted agents.

Evolving perspectives in MOGAD: a comprehensive research update

In this podcast, key opinion leaders Hans Lassman, MD, Medical University of Vienna; Vyanka Redenbaugh, MD, Mayo Clinic College of Medicine; Torge Rempe, MD, PhD, University of Florida College of Medicine; and Kazuo Fujihara, MD, PhD, Fukushima Medical University School of Medicine, give a comprehensive overview of the current research landscape in MOGAD, including its differentiation from MS, diagnostic techniques, predictors of relapse, and an ongoing clinical trial investigating an interleukin-6 targeted monoclonal antibody in the treatment of relapsing MOGAD.

Artificial intelligence: a new era in neurology

In this podcast, Tiago Outeiro, PhD, University Medical Center Göttingen, Göttingen, Germany; Chia-Chun Chiang, MD, Mayo Clinic, Rochester, MN; and Daniel Goldenholz, MD, PhD, Beth Israel Deaconess Medical Center, Boston, MA, engage in a thought-provoking discussion on the latest developments in AI application. They explore how AI's predictive capabilities could revolutionize basic science, its potential role in the diagnosis and treatment of headache disorders, and the current and prospective uses of AI across different fields of neurology.
Join us in this exciting exploration of AI's potential to reshape neurology, its existing successes, and the exciting opportunities it holds for the future.

The wearables revolution in neurology

Neurologists and researchers are increasingly harnessing the power of wearables to gather real-time, high-quality data about patients' neurological conditions.
We are joined by leading neurology experts who will share their insights into the diverse applications of wearables in the fields of epilepsy, movement disorders, multiple sclerosis and sleep disorders, offering a glimpse into the future of neurology.

ɑ-syn in Parkinson’s disease: cause, biomarker, & treatment target

The causative nature of alpha-synuclein (ɑ-syn) accumulation in Parkinson's disease (PD) pathophysiology has been a subject of debate among researchers, ever since its identification in Lewy bodies.
In this episode, experts discuss our current understanding of the role of ɑ-syn in PD, as well as the possibility that the loss of normal ɑ-syn function may be more relevant than the accumulation of insoluble ɑ-syn. We will hear from researchers working to improve the diagnosis and monitoring of PD, with the exciting development of novel ɑ-syn-PET tracers and seed amplification assays that can detect early PD with high sensitivity and specificity.

Biomarkers for disease progression and treatment response in MS

Biomarker development and discovery have been an important point in multiple sclerosis (MS) research for many years.
In this podcast, Elias Sotirchos, MD, Johns Hopkins University School of Medicine, Baltimore, MD; Ferhan Qureshi, VP – Biomarker Product Development, Octave, Menlo Park, CA; and Shane Arsenault, MD, Memorial University of Newfoundland, St. John’s, Canada, discuss recent updates on the development and validation of biomarkers that can predict disability progression, monitor ongoing disease activity, and assess treatment response.

Debating bridging thrombolysis at ISC 2023

In this episode, key opinion leaders debate the value of bridging therapy for endovascular thrombectomy following recent reports from several large scale randomized controlled trials. What evidence do we have and what is the best way forward? 
With Manon Kappelhof, Johannes Kaesmacher, Urs Fischer, Yvo B. Roos, and Thanh Nguyen.